GlassScriptPhysician profile
Meredith B Huffman
NPI 1053674044
$7,017.12
in general payments reported to CMS, 2019-2025
24 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,323 · 2022: $1,488 · 2023: $1,838 · 2024: $1,969 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,021 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,020.78 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,335.83 | 2021-2025 | |
| Abbvie INC. | $1,241.68 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $651.55 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $582.70 | 2021-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $509.27 | 2021-2025 | Absorica Ld, Winlevi, Odomzo |
| Janssen Biotech, INC. | $424.51 | 2021-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $366.74 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $247.27 | 2021-2022 | |
| Amgen INC. | $211.46 | 2021-2024 | Otezla |
| Lilly USA, LLC | $193.88 | 2021-2024 | Olumiant, Taltz |
| Incyte Corporation | $188.64 | 2021-2023 | Opzelura |
| Allergan, INC. | $181.92 | 2021 | |
| Pfizer INC. | $167.08 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $163.27 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.65 | 2023-2025 | Spevigo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $124.28 | 2022-2025 | Bimzelx |
| Verrica Pharmaceuticals INC. | $79.90 | 2023-2024 | Ycanth |
| Galderma Laboratories, L.P. | $49.33 | 2023-2024 | Twyneo, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.18 | 2023-2024 | Arazlo, Cabtreo |
| Almirall LLC | $23.93 | 2021 | |
| Dermavant Sciences, INC. | $22.85 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $22.50 | 2021 | |
| Sandoz INC. | $21.37 | 2024 | Hyrimoz |
| Dermira, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.